Abstract: A woven fabric comprising: a) A first layer of first uncrimped weft filaments; b) a second layer of second uncrimped weft filaments; wherein for each of the first uncrimped weft filaments there is one corresponding second uncrimped weft filament, and vice versa, to form successive filament pairs of first and second uncrimped weft filaments, c) crimped warp filaments having four different weave types c1-c4, but each weave type consisting of entwining around first uncrimped weft filaments; passing between first and second uncrimped weft filaments; entwining around second uncrimped weft filaments; and passing again between first and second uncrimped weft filaments; and d) uncrimped warp filaments passing between the first uncrimped weft filaments and the second uncrimped weft filaments of all filament pairs; wherein the fabric does not comprise crimped warp filaments which entwine around the first uncrimped weft filaments and the second uncrimped weft filaments in alternating manner.

Abstract: A belt carcass (1) comprising one, two, or more than two impregnated layers (21,22,23,24,25); characterised in that i) each impregnated layer (21,22,23,24,25) comprises, or consists essentially of, a non-wovenfabric (3,301,302,303,304,305,306,307,308) and an impregnation material (4,401,402,403,404,405,406,407,408) comprising, or consisting essentially of, a first thermoplastic, first thermoplastic elastomer, first elastomer or first thermoset and optional additives; whereby, if there are two or more such impregnated layers (21,22,23,24,25), they are adjacent to each other, ii) if the belt carcass (1) comprises one or more such impregnated layers (21,22,23,24,25), then reinforcing filaments extending at least in part in one given direction and being in the form of one filament layer (51) are embedded in the non-woven fabric (3) of exactly one of said impregnated layers (21); or if the belt carcass (1) comprises two or more such impregnated layers (21,22,23,24,25), then reinforcing filaments extending at least

Abstract: The present invention is directed to 2,2-difluorodioxolo compounds that are antagonists of A2A receptor. The present invention is also directed to uses of the 2,2-difluorodioxolo compounds described herein in the potential treatment or prevention of neurological disorders and diseases in which A2A receptor are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds and to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which A2A receptors are involved.

Abstract: An abrasive product comprising an impregnated woven fabric comprising: a) A first layer of first uncrimped weft multifilaments (301-308) b) a second layer of second uncrimped weft multifilaments (309-316); wherein for each of the first uncrimped weft multifilaments (301-308) there is one corresponding second uncrimped weft multifilament (309-316), and vice versa, to form successive multifilament pairs (301/309, 302/310, 303/311, 304/312, 305/313, 306/314, 307/315, 308/316) of first and second uncrimped weft multifilaments; c) crimped warp filaments (41-44) having four different weave types d-c4, but each weave type consisting of entwining around first uncrimped weft multifilaments; passing between first and second uncrimped weft multifilaments; entwining around second uncrimped weft multifilaments; and passing again between first and second uncrimped weft multifilaments; d) uncrimped warp filaments (4) passing between first (301-308) and second (309-316) uncrimped weft multifilaments of all multifilament pair

Abstract: A sheet material (1) consisting of an mixture consisting essentially of: a) 10-50 percent by weight of random-oriented fibres, and; b) 90-50 percent by weight of a thermoplastic or thermoplastic elastomer; the weight percentages being based on the overall homogeneous mixture; and the sheet material having at room temperature a Shore D hardness of 40 to 85, preferably of 40 to 60, more preferably of 45 to 55. The sheet material (1) is used as a support in punching applications or as the top layer in punching belts (2).

Abstract: A woven fabric comprising: a) A first layer of first uncrimped weft filaments; b) a second layer of second uncrimped weft filaments; wherein for each of the first uncrimped weft filaments there is one corresponding second uncrimped weft filament, and vice versa, to form successive filament pairs of first and second uncrimped weft filaments, c) crimped warp filaments having four different weave types c1-c4, but each weave type consisting of entwining around first uncrimped weft filaments; passing between first and second uncrimped weft filaments; entwining around second uncrimped weft filaments; and passing again between first and second uncrimped weft filaments; and d) uncrimped warp filaments passing between the first uncrimped weft filaments and the second uncrimped weft filaments of all filament pairs; wherein the fabric does not comprise crimped warp filaments which entwine around the first uncrimped weft filaments and the second uncrimped weft filaments in alternating manner.

Abstract: A sheet material (1) consisting of an mixture consisting essentially of: a) 10-50 percent by weight of random-oriented fibres, and; b) 90-50 percent by weight of a thermoplastic or thermoplastic elastomer; the weight percentages being based on the overall homogeneous mixture; and the sheet material having at room temperature a Shore D hardness of 40 to 85, preferably of 40 to 60, more preferably of 45 to 55. The sheet material (1) is used as a support in punching applications or as the top layer in punching belts (2).

Abstract: This invention relates to imidazopyridyl compounds of the structural formula: or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthase.

Abstract: The present invention is directed to 2,2-difluorodioxolo compounds that are antagonists of A2A receptor. The present invention is also directed to uses of the 2,2-difluorodioxolo compounds described herein in the potential treatment or prevention of neurological disorders and diseases in which A2A receptor are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds and to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which A2A receptors are involved.

Abstract: This invention relates to imidazopyridyl compounds of the structural formula: or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthase.

Abstract: This invention relates to imidazopyridyl compounds of the structural formula: I or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthase.

Abstract: A compound having the structure: useful for treating hypertension, Pulmonary Arterial Hypertension (PAH), congestive heart failure, conditions resulting from excessive water retention, cardiovascular disease, diabetes, oxidative stress, endothelial dysfunction, cirrhosis, pre-eclampsia, osteoporosis or nephropathy.

Abstract: This invention relates to imidazopyridyl compounds of the structural formula: I or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthase.

Abstract: A polymorph of brimonidine pamoate having the formula exhibits characteristics disclosed herein. The polymorph is included in a composition, device, or implant for use in the treatment or control of elevated intraocular pressure or in the neuroprotection of components of a neurological tissue to prevent progressive degeneration of such components. In particular, such a composition, device, or implant can be used to provide neuroprotection to cells and components of the optic nerve system.

Abstract: A polymorph of brimonidine pamoate having the formula exhibits characteristics disclosed herein. The polymorph is included in a composition, device, or implant for use in the treatment or control of elevated intraocular pressure or in the neuroprotection of components of a neurological tissue to prevent progressive degeneration of such components. In particular, such a composition, device, or implant can be used to provide neuroprotection to cells and components of the optic nerve system.

Abstract: A compound having the structure: useful for treating hypertension, Pulmonary Arterial Hypertension (PAH), congestive heart failure, conditions resulting from excessive water retention, cardiovascular disease, diabetes, oxidative stress, endothelial dysfunction, cirrhosis, pre-eclampsia, osteoporosis or nephropathy.

Abstract: A compound having the structure wherein Y is selected from the group consisting of —C(O)OR2, —C(O)NHR8, —C(CH2)1-2OR3, OH, and or a pharmaceutically acceptable salt thereof, and methods of using the compounds for treating hypertension.

Abstract: A brimonidine pamoate polymorph exhibits characteristics disclosed herein, wherein the brimonidine pamoate has the following formula The polymorph is included in a composition, device, or implant for use in the treatment or control of elevated intraocular pressure or in the neuroprotection of components of a neurological tissue to prevent progressive degeneration of such components. In particular, such a composition, device, or implant can be used to provide neuroprotection to cells and components of the optic nerve system.

Abstract: A compound having the structure useful for treating hypertension, Pulmonary Arterial Hypertension (PAH), congestive heart failure, conditions resulting from excessive water retention, cardiovascular disease, diabetes, oxidative stress, endothelial dysfunction, cirrhosis, pre-eclampsia, osteoporosis or nephropathy.

Abstract: A compound having the structure useful for treating hypertension, Pulmonary Arterial Hypertension (PAH), congestive heart failure, conditions resulting from excessive water retention, cardiovascular disease, diabetes, oxidative stress, endothelial dysfunction, cirrhosis, pre-eclampsia, osteoporosis or nephropathy.